Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study

Leukemia

Volumn 31, Issue 7, 2017, Pages 1525-1531

  Hochhaus, A ^a   Masszi, T ^b   Giles, F J ^c   Radich, J P ^d   Ross, D M ^e   Gomez Casares M T ^f   Hellmann, A ^g   Stentoft, J ^h   Conneally, E ⁱ   Garcia Gutierrez V ^j   Gattermann, N ^k   Wiktor Jedrzejczak, W ^l   Le Coutre, P D ^m   Martino, B ⁿ   Saussele, S ^o   Menssen, H D ^p   Deng, W ^p   Krunic, N ^q   Bedoucha, V ^p   Saglio, G ^r  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Szent Laszlo Hospital   (Hungary)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e SA Pathology   (Australia)

^f HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ ST JAMES S HOSPITAL   (Ireland)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^l MEDICAL UNIVERSITY OF WARSAW   (Poland)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^o UNIVERSITY OF HEIDELBERG   (Germany)

^p NOVARTIS PHARMA AG   (Switzerland)

^q NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^r UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; BILIRUBIN; GLUCOSE; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE PAIN; BRAIN ISCHEMIA; CANCER PATIENT; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEUKOPENIA; LIMB PAIN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; MYALGIA; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REAL TIME POLYMERASE CHAIN REACTION; RETREATMENT; RHINOPHARYNGITIS; SPINAL PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FREE REMISSION; TREATMENT RESPONSE; CLINICAL TRIAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PSYCHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY OF LIFE;

EID: 85015700652     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.63     Document Type: Article

References (34)

1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, v1.2017. Available at: https://www.nccn.org/professionals/physician-gls/pdf/cml.pdf (last accessed 6 December 2016).
3. Boquimpani CM, Szczudlo T, Mendelson E, Benjamin K, Masszi T. Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR). Blood 2014; 124: (abstract 4547).
4. Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 2016; 101: 717-723.
5. Ross D, Villemagne-Sanchez L, Hall K, Gough K, Kashima Y, O'Callaghan C et al. Factors that influence patient willingness to attempt treatment-free remission in chronic myeloid leukaemia. Haematologica 2016; 101: 238.
6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
7. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014; 32: 424-430.
8. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study. Blood 2013; 122: 515-522.
9. Mori S, Le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C et al. Late relapses, up to 45 months after imatinib discontinuation: results from the ISAV study. Haematologica 2016; 101: 62-63.
10. Richter J, Mahon FX, Guilhot J, Hjorth-Hansen H, Almeida A, Janssen JJ et al. Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial. Haematologica 2016; 101: 22-23.
11. Rea D, Nicolini FE, Tulliez M, Rousselot P, Guilhot F, Gardembas M et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months-on behalf of the French CML Group Filmc. Blood 2014; 124: (abstract 811).
12. Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015; 2: e528-e535.
13. Takahashi N, Nishiwaki K, Nakaseko C, Wakita H, Sano K, Ohwada C et al. Successful treatment free remission in CML after 2 year consolidation with nilotinib of an MR4.5 response level achieved originally with imatinib treatment: first report from STAT2 trial in Japan. Haematologica 2016; 101: 61.
14. Rea D, Rousselot P, Guilhot F, Tulliez M, Nicolini FE, Guerci-Bresler A et al. Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood 2012; 120: (abstract 916).
15. Hughes TP, Boquimpani C, Takahashi N, Benyamini N, Clementino NCD, Shuvaev V et al. Results from ENESTop: treatment-free remission following switch to nilotinib in patients with chronic myeloid leukemia in chronic phase. Haematologica 2016; 101: 65.
16. 4.5 after switching from imatinib (IM) to nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): preliminary results from ENESTgoal. Blood 2015; 126: (abstract 4050).
17. Rea D, Rosti G, Cross NCP, Hellman A, Niederwiester D, Pungolino E et al. Enestpath: a phase III study to assess the effect of nilotinib treatment duration on treatment-free remission (TFR) in chronic phase-chronic myeloid leukemia (CP-CML) patients (pts) previously treated with imatinib: interim analysis from the first year of induction phase. Blood 2015; 126: (abstract 4040).
18. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013; 122: 641-647.
19. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727-1736.
20. Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn 2009; 11: 4-11.
21. Richter J, Söderlund S, Lübking A, Dreimane A, Lotfi K, Markevärn B et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 2014; 32: 2821-2823.
22. Mahon FX, Richter J, Guilhot J, Muller MC, Dietz C, Porkka K et al. Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI study. Blood 2014; 124: (abstract 151).
23. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al. Reply to J. Richter et al. J Clin Oncol 2014; 32: 2823-2825.
24. Berger MG, Perieira B, Oris C, Saugues S, Cony-Makhoul P, Gardembas M et al. Osteoarticular pain after discontinuation of tyrosine kinase inhibitors (TKI): a French cohort. Blood 2015; 126: (abstract 137).
25. Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 2016; 30: 1638-1647.
26. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016; 128: 17-23.
27. Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular response following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999-1003.
28. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044-1054.
29. Hochhaus A, Rosti G, Cross NCP, Steegmann JL, le Coutre P, Ossenkoppele G et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2016; 30: 57-64.
30. Hochhaus A, Saglio G, Hughes TP, Larson RA, Taningco L, Deng W et al. Impact of treatment with frontline nilotinib (NIL) vs imatinib (IM) on sustained deep molecular response (MR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 2015; 126: (abstract 2781).
31. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE et al. Long term follow-up after imatinib cessation for patients indeep molecular response: the update results of the STIM1 study. Blood 2013; 122: (abstract 255).
32. Mahon FX, Nicolini FE, Noël M, Escoffre M, Charbonnier A, Rea D et al. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood 2013; 122: (abstract 654).
33. Mahon F, Richter J, Guilhot J, Hjorth-Hansen H, Almeida A, Janssen JWM et al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood 2016; 128: (abstract 787).
34. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016; 34: 2851-2857.